T細胞を免疫排除された腫瘍に駆動する合成サイトキンの回路
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。エンジニアリングされたCAR T細胞は,局所的にIL-2を生成することで,固体腫瘍抑制を克服し,全身の毒性なしに腫瘍の浸透とクリアランスを強化します. この合成生物学的なアプローチは T細胞の活性化と抗腫瘍反応を可能にし 腫瘍抑制メカニズムを回避します
科学分野
- 免疫学
- 合成生物学
- 腫瘍学
背景
- 化学抗原受容体 (CAR) T細胞は,免疫抑制性マイクロ環境により,固体腫瘍で課題に直面する.
- 腫瘍に浸透するCAR T細胞は,局所的な免疫抑制によってしばしば無効になります.
研究 の 目的
- 固体腫瘍の免疫抑制を 克服できるCAR T細胞を設計する
- CAR T細胞の有効性を高めるため,局所的なサイトカイン生成のための合成回路を開発する.
- 腫瘍の微小環境抑制から独立したCAR T細胞活性化の方法を調査する.
主な方法
- CAR T細胞の局所的なIL-2生成を誘導するシンノッチ受容体を設計する.
- オトクリンおよびT細胞受容体 (TCR) /CARから独立したIL-2誘導回路の設計.
- 免疫抑制性腫瘍モデルにおけるCAR T細胞の浸透,拡大,および腫瘍クリアランスの評価.
- エンジニアリングされたCAR T細胞の全身性毒性の評価
主要な成果
- 局所的なIL-2生成回路を持つ設計されたCAR T細胞は,腫瘍の浸透とクリアランスを強力に強化しました.
- 最も効果的な回路は,TCR/CAR信号から独立して,免疫抑制を回避した.
- エンジニアリングされた細胞は 腫瘍に足場を確立し CAR媒介による拡大と殺戮を開始しました
- 局所的なIL-2誘導戦略では全身性毒性は観察されなかった.
結論
- 合成生物学では 腫瘍抑制を克服するために T細胞回路を再構成できます
- 設計されたCAR T細胞による局所的なIL-2生成は,固体腫瘍に対する有効な戦略です.
- このアプローチは CAR T 細胞の活性化と抗腫瘍反応を可能にし,重要な腫瘍抑制メカニズムを回避します.
関連する概念動画
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...